CETP inhibitors

US8334290B2 · kind B2 · utility

Assignee

• Merck Sharp & Dohme LLC · US

Inventors

• Amjad Ali · Freehold, US
• Julianne A. Hunt · Scotch Plains, US
• Florida Kallashi · Yonkers, US
• Jennifer Kowalchick · Clark, US
• Dooseop Kim · Scotch Plains, US
• Cameron Smith · Lawrenceville, US
• Peter J. Sinclair · Highland Park, US
• Ramzi F. Sweis · Vernon Hills, US
• Gayle E. Taylor · Jersey City, US
• Christopher F. Thompson · Arlington, US
• Liya Chen · East Brunswick Township, US
• Nazia Quraishi · Bethesda, US

Key dates

• Filing date: Oct 30, 2006
• Grant date: Dec 18, 2012
• Expiry date: Apr 9, 2027

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D498/04
• WIPO field: Organic fine chemistry
• WIPO sector: Chemistry

Abstract

Compounds of Formula I, including pharmaceutically acceptable salts of the compounds, are CETP inhibitors, and are useful for raising HDL-cholesterol, reducing LDL-cholesterol, and for treating or preventing atherosclerosis.